Brotchie JM - Search Results

1

Quantitative assessment of dyskinesias in subhuman primates.

Brotchie JM, Fox SH. Brotchie JM, et al. Mov Disord. 1999;14 Suppl 1:40-7. Mov Disord. 1999. PMID: 10493402 Review. No abstract available.

2

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.

Fox SH, Lang AE, Brotchie JM. Fox SH, et al. Among authors: brotchie jm. Mov Disord. 2006 Oct;21(10):1578-94. doi: 10.1002/mds.20936. Mov Disord. 2006. PMID: 16874752 Review.

3

The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.

Johnston TH, Fox SH, Piggott MJ, Savola JM, Brotchie JM. Johnston TH, et al. Among authors: brotchie jm. Mov Disord. 2010 Oct 15;25(13):2084-93. doi: 10.1002/mds.23172. Mov Disord. 2010. PMID: 20824735

4

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR. Johnston TH, et al. Among authors: brotchie jm. Mov Disord. 2019 May;34(5):708-716. doi: 10.1002/mds.27565. Epub 2018 Dec 21. Mov Disord. 2019. PMID: 30575996

5

The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.

Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. Henry B, et al. Among authors: brotchie jm. Mov Disord. 1999 Sep;14(5):744-53. doi: 10.1002/1531-8257(199909)14:5<744::aid-mds1006>3.0.co;2-7. Mov Disord. 1999. PMID: 10495035

6

5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease.

Fox SH, Brotchie JM. Fox SH, et al. Among authors: brotchie jm. Mov Disord. 2000 Nov;15(6):1064-9. doi: 10.1002/1531-8257(200011)15:6<1064::aid-mds1002>3.0.co;2-c. Mov Disord. 2000. PMID: 11104187

7

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Fox SH, et al. Mov Disord. 2002 Nov;17(6):1180-7. doi: 10.1002/mds.10289. Mov Disord. 2002. PMID: 12465055

8

Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.

Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. Fox SH, et al. Among authors: brotchie jm. Mov Disord. 2002 Jan;17(1):145-9. doi: 10.1002/mds.1280. Mov Disord. 2002. PMID: 11835452 Clinical Trial.

9

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM. Savola JM, et al. Among authors: brotchie jm. Mov Disord. 2003 Aug;18(8):872-83. doi: 10.1002/mds.10464. Mov Disord. 2003. PMID: 12889076

10

Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.

Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM. Henry B, et al. Among authors: brotchie jm. Exp Neurol. 2003 Oct;183(2):458-68. doi: 10.1016/s0014-4886(03)00064-5. Exp Neurol. 2003. PMID: 14552886

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

213 results

Search Page

Filters